GATA3 immunohistochemical stain is a highly sensitive tool for distinguishing between upper urothelial tract urothelial carcinoma and lung squamous cell carcinoma and adenocarcinoma

Plessis, Justin du; Newman, Marsali; Williams, David S.

doi:10.1016/j.pathol.2015.12.168

Search citation statements

Order By: Relevance

Paper Sections

Select...

Immunohistochemical Staining1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IHC staining and images analysis were carried out following the instructions described in previous studie. 17 Anti-FOXD4 antibody (1:100, Santa Cruz, USA) was used in the present study. The antibody dilution medium was used as a negative control.…”

Section: Immunohistochemical Stainingmentioning

confidence: 99%

FOXD4 induces tumor progression in colorectal cancer by regulation of the SNAI3/CDH1 axis

Chen

Aihemaiti

Zhang

et al. 2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

Colorectal cancer (CRC) is ranked third as the most common malignancy, and it develops into metastasis at a high rate. Importantly, distant metastasis is considered to be a key factor for colorectal therapy. In the present study, we identified FOXD4, a transcription factor belonging to the forkhead/winged helixbox (FOX) family, as a novel biomarker for diagnosis and treatment of patients with CRC. We revealed that FOXD4 was up-regulated in CRC tissues and increased the metastatic ability of CRC cells. Additionally, FOXD4 affected the metastasis of CRC by inducing the epithelial-mesenchymal transition (EMT) process. Furthermore, FOXD4 could directly bind the SNAI3 promoter during EMT in CRC and then facilitate CRC metastasis. In summary, the present research strongly suggests that FOXD4 is a valuable marker for CRC, and that targeting FOXD4 may be a novel strategy for enhancing the treatment outcomes of CRC therapy ARTICLE HISTORY

show abstract

Section: Immunohistochemical Stainingmentioning

confidence: 99%